Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Danuglipron in Hepatic Impairment
NCT04604496Phase 1Completed
- Sponsor
- Pfizer
- Start
- Dec 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of danuglipron in type 2 diabetes mellitus (T2DM) and obesity (4 arms), sponsored by Pfizer. Primary endpoints: Maximum Plasma Concentration at 48 hours, Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time at 48 hours and 2 more. Started Dec 2020; status: completed.
02
Drugs
danuglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT04604496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04604496.